HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:HYL - BE0974363955 - Common Stock
8.06 EUR
+0.06 (+0.75%)
Overall HYL gets a fundamental rating of 4 out of 10. We evaluated HYL against 55 industry peers in the Pharmaceuticals industry. The financial health of HYL is average, but there are quite some concerns on its profitability. HYL is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- HYL had negative earnings in the past year.
- HYL had a negative operating cash flow in the past year.
- HYL had negative earnings in each of the past 5 years.
- In the past 5 years HYL always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -17.31%, HYL is not doing good in the industry: 78.18% of the companies in the same industry are doing better.
- The Return On Equity of HYL (-22.20%) is worse than 76.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.31% | ||
| ROE | -22.2% | ||
| ROIC | N/A |
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HYL has a Gross Margin of 96.63%. This is amongst the best in the industry. HYL outperforms 98.18% of its industry peers.
- In the last couple of years the Gross Margin of HYL has grown nicely.
- The Profit Margin and Operating Margin are not available for HYL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
2. Health
2.1 Basic Checks
- HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, HYL has about the same amount of shares outstanding.
- Compared to 5 years ago, HYL has more shares outstanding
- Compared to 1 year ago, HYL has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 13.52 indicates that HYL is not in any danger for bankruptcy at the moment.
- The Altman-Z score of HYL (13.52) is better than 96.36% of its industry peers.
- HYL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.06, HYL belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.52 |
ROIC/WACCN/A
WACC7.92%
2.3 Liquidity
- HYL has a Current Ratio of 3.82. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of HYL (3.82) is better than 94.55% of its industry peers.
- HYL has a Quick Ratio of 3.80. This indicates that HYL is financially healthy and has no problem in meeting its short term obligations.
- HYL's Quick ratio of 3.80 is amongst the best of the industry. HYL outperforms 94.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 3.8 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 46.05% over the past year.
- HYL shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.15%.
- The Revenue has been growing by 147.54% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.01%
Revenue 1Y (TTM)44.15%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%-27.33%
3.2 Future
- HYL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.80% yearly.
- The Revenue is expected to grow by 94.06% on average over the next years. This is a very strong growth
EPS Next Y38.32%
EPS Next 2Y31.09%
EPS Next 3Y44.8%
EPS Next 5YN/A
Revenue Next Year77.8%
Revenue Next 2Y99.59%
Revenue Next 3Y94.06%
Revenue Next 5YN/A
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- HYL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HYL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- HYL's earnings are expected to grow with 44.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y44.8%
5. Dividend
5.1 Amount
- No dividends for HYL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ
What is the fundamental rating for HYL stock?
ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR.
What is the valuation status of HYLORIS PHARMACEUTICALS SA (HYL.BR) stock?
ChartMill assigns a valuation rating of 1 / 10 to HYLORIS PHARMACEUTICALS SA (HYL.BR). This can be considered as Overvalued.
Can you provide the profitability details for HYLORIS PHARMACEUTICALS SA?
HYLORIS PHARMACEUTICALS SA (HYL.BR) has a profitability rating of 1 / 10.
What is the earnings growth outlook for HYLORIS PHARMACEUTICALS SA?
The Earnings per Share (EPS) of HYLORIS PHARMACEUTICALS SA (HYL.BR) is expected to grow by 38.32% in the next year.